1. Home
  2. LAES vs ENGN Comparison

LAES vs ENGN Comparison

Compare LAES & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SEALSQ Corp

LAES

SEALSQ Corp

N/A

Current Price

$3.92

Market Cap

821.2M

Sector

Technology

ML Signal

N/A

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

N/A

Current Price

$7.30

Market Cap

647.1M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
LAES
ENGN
Founded
2022
1999
Country
Switzerland
Canada
Employees
N/A
82
Industry
Semiconductors
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
821.2M
647.1M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
LAES
ENGN
Price
$3.92
$7.30
Analyst Decision
Buy
Buy
Analyst Count
1
5
Target Price
$7.00
$21.00
AVG Volume (30 Days)
4.0M
362.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$64.88
N/A
Revenue Next Year
$94.93
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.12
$2.66
52 Week High
$8.71
$12.25

Technical Indicators

Market Signals
Indicator
LAES
ENGN
Relative Strength Index (RSI) 46.18 35.22
Support Level $3.44 $6.03
Resistance Level $3.96 $9.63
Average True Range (ATR) 0.26 0.67
MACD 0.01 -0.35
Stochastic Oscillator 40.82 20.00

Price Performance

Historical Comparison
LAES
ENGN

About LAES SEALSQ Corp

SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America.

About ENGN enGene Holdings Inc.

enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Share on Social Networks: